Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC009339 | Panoply™ Human MDK Knockdown Stable Cell Line | Inquiry |
| CSC-SC009339 | Panoply™ Human MDK Over-expressing Stable Cell Line | Inquiry |
| CLOE-1579 | Human MDK Insect Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD09784Z | Human MDK adenoviral particles | Inquiry |
| LV17997L | human MDK (NM_001012333) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH182567 | shRNA set against Mouse Mdk(NM_010784.4) | Inquiry |
| SHH182549 | shRNA set against Rat Mdk(NM_030859.2) | Inquiry |
| SHH182603 | shRNA set against Mouse Mdk(NM_001012336.1) | Inquiry |
| SHH182621 | shRNA set against Mouse Mdk(NM_001012335.1) | Inquiry |
| SHH339651 | shRNA set against Human MDK (NM_002391.4) | Inquiry |
| SHH339655 | shRNA set against Mouse MDK (NM_010784.4) | Inquiry |
| SHH339659 | shRNA set against Rat MDK (NM_030859.2) | Inquiry |
| SHW002742 | shRNA set against Chicken MDK (NM_001113289) | Inquiry |
| SHW015123 | shRNA set against Danio rerio MDKB (NM_131716) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB180435 | Rabbit MDK ORF clone (NM_001082167.1) | Inquiry |
| CDCR249629 | Mouse Mdk ORF Clone(NM_010784.4) | Inquiry |
| CDFR012391 | Rat Mdk cDNA Clone(NM_030859.2) | Inquiry |
| MiUTR1M-07022 | MDK miRNA 3'UTR clone | Inquiry |
| MiUTR1M-07023 | MDK miRNA 3'UTR clone | Inquiry |
| MiUTR1M-07024 | MDK miRNA 3'UTR clone | Inquiry |
| MiUTR1R-03744 | MDK miRNA 3'UTR clone | Inquiry |
| MiUTR3H-01522 | MDK miRNA 3'UTR clone | Inquiry |
| MiUTR3H-01523 | MDK miRNA 3'UTR clone | Inquiry |
| MiUTR3H-01524 | MDK miRNA 3'UTR clone | Inquiry |
| CDCB164217 | Chicken MDK ORF Clone (NM_001113289) | Inquiry |
| CDCB176598 | Danio rerio MDKB ORF Clone (NM_131716) | Inquiry |
| CDCB196035 | Rabbit LOC103351245 ORF clone (XM_008269615.1) | Inquiry |
| CDCL131521 | Human Mdk ORF clone (NM_001012335.1) | Inquiry |
| CDCR379428 | Rat Mdk ORF Clone(NM_030859.2) | Inquiry |
| CDCS406487 | Human MDK ORF Clone (BC011704) | Inquiry |
The MDK (Midkine) gene is located on chromosome 11q11.2 and encodes a heparin-binding growth factor that, together with pleiotrophin (PTN), constitutes the midkine family. The protein structure includes two highly positively charged domains (N-cluster and C-cluster) and highly conserved cysteine residues. MDK binds to multiple receptors via heparin chains:
MDK expression exhibits spatiotemporal specificity. It is highly expressed during embryonic development, especially in the kidney and nervous system, but significantly downregulated in adulthood. It is reactivated in response to tissue injury or pathological conditions. Single-cell sequencing data reveal that MDK expression in infiltrative basal cell carcinoma (iBCC) is 4.7 times higher than in nodular subtypes and is positively correlated with tumor invasion depth (r = 0.83, P < 0.001).
MDK regulates development, repair, and malignant transformation through a complex receptor network:
Neurodevelopment and Injury Repair: MDK binds to PTPRZ1 to promote neuronal migration and activates the PI3K/AKT pathway via LRP1 to support neuronal survival. In brain injury models, MDK overexpression increases neural progenitor proliferation by 2.1-fold and improves functional recovery by 40%. However, in Alzheimer's disease, aberrant MDK deposition accelerates Aβ oligomerization and neurotoxic plaque formation.
Tumor Microenvironment Remodeling: The oncogenic roles of MDK involve three key pathways:
Tissue Regeneration vs. Fibrosis: After cardiac injury, MDK promotes repair via macrophage-dependent angiogenesis (infarct area reduced by 35%). However, in renal fibrosis, sustained MDK expression activates fibroblasts through NOTCH2 signaling, increasing collagen deposition by 2.3-fold.
Figure 1. MDK receptor candidates and signaling pathways. (Neumaier EE, et al., 2023)
Early Diagnosis of Lung Cancer: MDK shows a high diagnostic value in lung cancer with an AUC of 0.878, outperforming traditional markers such as CEA. When combined with AI-assisted immunohistochemical analysis, the early detection rate (stage I) increases to 89%.
Targeted Cancer Therapy:
Neural Repair and Regeneration: MDK siRNA encapsulated in chitosan nanoparticles (80 nm diameter, +35 mV zeta potential) effectively penetrates the blood–spinal cord barrier in spinal cord injury models, reducing MDK expression by 73% and glial scar formation by 50%.
The multifunctionality of MDK presents a therapeutic paradox: complete inhibition may impair tissue repair, while partial blockade may be insufficient for tumor control. Proposed solutions include:
Microenvironment-responsive prodrugs, such as MDK inhibitors conjugated with MMP–9–cleavable linkers.
Personalized therapeutics based on receptor expression profiles, such as using antibodies for LRP1-high patients or small molecules for ALK-mutant tumors.
Advances in single-cell spatial transcriptomics will help elucidate the dynamic regulation of MDK in tumor heterogeneity, enabling more precise and adaptive intervention strategies.
References: